Zervimesine
Zervimesine (CT1812) is an orally active and brain penetrant sigma-2 receptor antagonist with a Ki of 8.5 nM. Zervimesine can be used for the research of Alzheimer’s disease[1].
Product Specifications
CAS Number
[1802632-22-9]
Product Name Alternative
CT1812; Sigma-2 receptor antagonist 1
UNSPSC
12352005
Target
Sigma Receptor
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/ct1812.html
Purity
99.01
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC1=CC=C(CCC(C)(N2CC3=C(C=C(S(=O)(C)=O)C=C3)C2)C)C=C1OC(C)(C)C
Molecular Formula
C24H33NO4S
Molecular Weight
431.59
References & Citations
[1]Izzo NJ, et al. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Alzheimers Dement. 2021 Aug;17 (8) :1365-1382.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Sigma 2 Receptor
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
YP-W16929-01 48 Tests
Human Baculoviral IAP repeat-containing protein 3 (BIRC3) ELISA Kit
Ask
View Details YP-W16929-02 96 Tests
Human Baculoviral IAP repeat-containing protein 3 (BIRC3) ELISA Kit
Ask
View Details MBS1025964-01 0.02 mg (E-Coli)
Recombinant Saccharomyces cerevisiae Suppressor of disruption of TFIIS (SDT1)
Ask
View Details MBS1025964-02 0.02 mg (Yeast)
Recombinant Saccharomyces cerevisiae Suppressor of disruption of TFIIS (SDT1)
Ask
View Details